Kinzalkomb

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Telmisartan, hydrochlorothiazide

Available from:

Bayer AG

ATC code:

C09DA07

INN (International Name):

telmisartan, hydrochlorothiazide

Therapeutic group:

Sredstva, ki delujejo na sistem renin-angiotenzin

Therapeutic area:

Hipertenzija

Therapeutic indications:

Zdravljenje esencialne hipertenzije. Kinzalkomb določen odmerek kombinacije (40 mg telmisartan / 12. 5 mg hydrochlorothiazide, 80 mg telmisartan / 12. 5 mg hydrochlorothiazide) je indicirano pri bolnikih, katerih krvni tlak ni ustrezno nadzorovan na telmisartan sam. Kinzalkomb določen odmerek kombinacije (80 mg telmisartan / 25 mg hydrochlorothiazide) je indicirano pri bolnikih, katerih krvni tlak ni ustrezno nadzorovan na Kinzalkomb (80 mg telmisartan / 12. 5 mg hydrochlorothiazide) ali pri bolnikih, ki so bili predhodno stabiliziranih na telmisartan in hydrochlorothiazide podana ločeno.

Product summary:

Revision: 39

Authorization status:

Pooblaščeni

Authorization date:

2002-04-19

Patient Information leaflet

                                49
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
ZA SHRANJEVANJE ZDRAVILA NI POSEBNIH TEMPERATURNIH OMEJITEV .
SHRANJUJTE V ORIGINALNI OVOJNINI ZA ZAGOTOVITEV ZAŠČITE PRED VLAGO.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Bayer AG
51368 Leverkusen
Nemčija
12.
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET
EU/1/02/214/001
14 tablet
EU/1/02/214/002
28 tablet
EU/1/02/214/003
28 x 1 tableta
EU/1/02/214/004
56 tablet
EU/1/02/214/005
98 tablet
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Kinzalkomb 40 mg/12,5 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
50
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC: {številka} [koda zdravila]
SN: {številka} [serijska številka]
NN: {številka} [nacionalna številka povračila stroškov za zdravilo
ali druga nacionalna številka za
identifikacijo zdravila]
51
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT PO 7 TABLET
1.
IME ZDRAVILA
Kinzalkomb 40 mg/12,5 mg tablete
telmisartan / hidroklorotiazid
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Bayer (Logo)
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
PON
TOR
SRE
ČET
PET
SOB
NED
52
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PERFORIRANI PRETISNI OMOT ZA ENKRATNI ODMEREK (28 X 1 TABLETA) ALI VSI
TISTI PRETISNI OMOTI, KI NE
VSEBUJEJO PO 7 TABLEt
1.
IME ZDRAVILA
Kinzalkomb 40 mg/12,5 mg tablete
telmisartan / hidroklorotiazid
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Bayer (Logo)
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
53
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA
1.
IME ZDRAVILA
Kinzalkomb 80 mg/12,5 mg tablete
telmisartan / hidroklorotiazid
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
1 tableta vsebuje 80 mg telmi
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Kinzalkomb 40 mg/12,5 mg tablete
Kinzalkomb 80 mg/12,5 mg tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Kinzalkomb 40 mg/12,5 mg tablete
Ena tableta vsebuje 40 mg telmisartana in 12,5 mg hidroklorotiazida.
Kinzalkomb 80 mg/12,5 mg tablete
Ena tableta vsebuje 80 mg telmisartana in 12,5 mg hidroklorotiazida
Pomožne snovi z znanim učinkom:
Kinzalkomb 40 mg/12,5 mg tablete
Ena tableta vsebuje 112 mg laktoze monohidrata, kar je enako 107 mg
brezvodne laktoze.
Ena tableta vsebuje 169 mg sorbitola (E420).
Kinzalkomb 80 mg/12,5 mg tablete
Ena tableta vsebuje 112 mg laktoze monohidrata, kar je enako 107 mg
brezvodne laktoze.
Ena tableta vsebuje 338 mg sorbitola (E420).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Tableta
Kinzalkomb 40 mg/12,5 mg tablete
Rdeča in bela podolgovata, dvoslojna 5,2 mm tableta z vtisnjeno kodno
številko 'H4'.
Kinzalkomb 80 mg/12,5 mg tablete
Rdeča in bela podolgovata, dvoslojna 6,2 mm tableta z vtisnjeno kodno
številko 'H8'.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravljenje esencialne hipertenzije.
Zdravilo Kinzalkomb, fiksna kombinacija (40 mg telmisartana/12,5 mg
hidroklorotiazida (HKTZ) in
80 mg telmisartana/12,5 mg HKTZ), je indicirano za odrasle, pri
katerih krvnega tlaka ne moremo
ustrezno uravnati s samim telmisartanom.
3
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Bolniki, pri katerih krvnega tlaka ne moremo ustrezno uravnati s samim
telmisartanom, jemljejo fiksno
kombinacijo enkrat na dan s tekočino, s hrano ali brez nje. Pred
prehodom na zdravljenje s fiksno
kombinacijo je priporočljivo, da najprej individualno prilagodimo
odmerka posameznih sestavin
kombinacije. Kadar bolnikovo klinično stanje dopušča, se lahko
odločimo za neposreden prehod z
monoterapije na zdravljenje s fiksno kombinacijo.

Zdravilo Kinzalkomb 40 mg/12,5 mg lahko dajemo enkrat na dan bolnikom,
pri katerih krvnega
tlaka ne moremo ustrezno nadzorovati z zdravilom Kinzalmono 40 mg

Zdravilo 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 14-09-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 14-09-2022
Public Assessment Report Public Assessment Report Bulgarian 06-11-2015
Patient Information leaflet Patient Information leaflet Spanish 14-09-2022
Public Assessment Report Public Assessment Report Spanish 06-11-2015
Patient Information leaflet Patient Information leaflet Czech 14-09-2022
Public Assessment Report Public Assessment Report Czech 06-11-2015
Patient Information leaflet Patient Information leaflet Danish 14-09-2022
Public Assessment Report Public Assessment Report Danish 06-11-2015
Patient Information leaflet Patient Information leaflet German 14-09-2022
Public Assessment Report Public Assessment Report German 06-11-2015
Patient Information leaflet Patient Information leaflet Estonian 14-09-2022
Public Assessment Report Public Assessment Report Estonian 06-11-2015
Patient Information leaflet Patient Information leaflet Greek 14-09-2022
Public Assessment Report Public Assessment Report Greek 06-11-2015
Patient Information leaflet Patient Information leaflet English 14-09-2022
Public Assessment Report Public Assessment Report English 06-11-2015
Patient Information leaflet Patient Information leaflet French 14-09-2022
Public Assessment Report Public Assessment Report French 06-11-2015
Patient Information leaflet Patient Information leaflet Italian 14-09-2022
Public Assessment Report Public Assessment Report Italian 06-11-2015
Patient Information leaflet Patient Information leaflet Latvian 14-09-2022
Public Assessment Report Public Assessment Report Latvian 06-11-2015
Patient Information leaflet Patient Information leaflet Lithuanian 14-09-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 14-09-2022
Public Assessment Report Public Assessment Report Lithuanian 06-11-2015
Patient Information leaflet Patient Information leaflet Hungarian 14-09-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 14-09-2022
Public Assessment Report Public Assessment Report Hungarian 06-11-2015
Patient Information leaflet Patient Information leaflet Maltese 14-09-2022
Public Assessment Report Public Assessment Report Maltese 06-11-2015
Patient Information leaflet Patient Information leaflet Dutch 14-09-2022
Public Assessment Report Public Assessment Report Dutch 06-11-2015
Patient Information leaflet Patient Information leaflet Polish 14-09-2022
Public Assessment Report Public Assessment Report Polish 06-11-2015
Patient Information leaflet Patient Information leaflet Portuguese 14-09-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 14-09-2022
Public Assessment Report Public Assessment Report Portuguese 06-11-2015
Patient Information leaflet Patient Information leaflet Romanian 14-09-2022
Public Assessment Report Public Assessment Report Romanian 06-11-2015
Patient Information leaflet Patient Information leaflet Slovak 14-09-2022
Public Assessment Report Public Assessment Report Slovak 06-11-2015
Patient Information leaflet Patient Information leaflet Finnish 14-09-2022
Public Assessment Report Public Assessment Report Finnish 06-11-2015
Patient Information leaflet Patient Information leaflet Swedish 14-09-2022
Public Assessment Report Public Assessment Report Swedish 06-11-2015
Patient Information leaflet Patient Information leaflet Norwegian 14-09-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 14-09-2022
Patient Information leaflet Patient Information leaflet Icelandic 14-09-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 14-09-2022
Patient Information leaflet Patient Information leaflet Croatian 14-09-2022
Public Assessment Report Public Assessment Report Croatian 06-11-2015

Search alerts related to this product

View documents history